The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

It is easy to take sight for granted when eyes are working as they should. When vision begins to diminish, people may seek ...

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

Bausch + Lomb (BLCO) announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, the first clinically validated, ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Bausch + Lomb announced today that, in response to a request from regulatory authorities, it authorized the exploration of a ...

Legislation under consideration in Trenton could modernize the scope of access to modern eye care in New Jersey.

The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

What’s normal ‘wear and tear’ due to age, and what’s something more serious? Here's how to tell if vision loss is normal or ...